Soichiro Yoshida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8501484/publications.pdf

Version: 2024-02-01

137 papers 3,191 citations

147801 31 h-index 50 g-index

146 all docs

146 docs citations

times ranked

146

4272 citing authors

#	Article	lF	CITATIONS
1	Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer. European Radiology, 2022, 32, 671-679.	4.5	16
2	Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response. Cancers, 2022, 14, 567.	3.7	5
3	Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements. European Journal of Radiology Open, 2022, 9, 100403.	1.6	4
4	Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma. Diagnostics, 2022, 12, 817.	2.6	4
5	Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 161.e15-161.e23.	1.6	6
6	Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imagingâ€Reporting and Data System in predicting muscleâ€invasive bladder cancer: A diagnostic metaâ€analysis. International Journal of Urology, 2022, 29, 196-196.	1.0	0
7	Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation. Abdominal Radiology, 2022, 47, 2178-2186.	2.1	8
8	Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non–muscle-invasive Bladder Cancer. European Urology Focus, 2021, 7, 366-372.	3.1	7
9	Can progressive siteâ€directed therapy prolong the efficacy of subsequent androgen receptor axisâ€targeted drugs in oligometastatic castrationâ€resistant prostate cancer?. International Journal of Urology, 2021, 28, 241-242.	1.0	2
10	Outcomes of gasless laparoendoscopic singleâ€port partial nephrectomy in 356 consecutive patients: Feasibility of a clampless and sutureless technique. International Journal of Urology, 2021, 28, 302-307.	1.0	6
11	Threeâ€dimensional analysis of systematic biopsyâ€derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance–ultrasound image fusion systems. International Journal of Urology, 2021, 28, 127-129.	1.0	1
12	Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunology, Immunotherapy, 2021, 70, 657-665.	4.2	20
13	Long-term survival after radical cystectomy and mesenteric lymph node dissection for squamous cell carcinoma arising from augmented bladder with lymph node metastasis: a case report. International Cancer Conference Journal, 2021, 10, 20-23.	0.5	O
14	Potential of Perfusion Magnetic Resonance Imaging to Predict Residual Renal Function after Radical Nephroureterectomy. Urologia Internationalis, 2021, 105, 507-513.	1.3	1
15	Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti–PD-1 Treatment Efficacy in Urothelial Carcinoma. International Journal of Molecular Sciences, 2021, 22, 535.	4.1	17
16	Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab., 2021, 9, e001564.		34
17	Wholeâ€body diffusionâ€weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond. International Journal of Urology, 2021, 28, 502-513.	1.0	7
18	Metastatic Diffusion Volume Based on Apparent Diffusion Coefficient as a Prognostic Factor in ⟨scp⟩Castrationâ€Resistant⟨/scp⟩ Prostate Cancer. Journal of Magnetic Resonance Imaging, 2021, 54, 401-408.	3.4	8

#	Article	IF	Citations
19	Diagnostic value of computed high b-value wholeâ€body diffusion-weighted imaging for primary prostate cancer. European Journal of Radiology, 2021, 137, 109581.	2.6	12
20	Editorial Comment to Longâ€ŧerm clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostateâ€ŧargeted treatment and metastasisâ€directed therapy. International Journal of Urology, 2021, 28, 756-756.	1.0	0
21	Nonmetastatic castrationâ€resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy. IJU Case Reports, 2021, 4, 228-230.	0.3	1
22	Nonuse of antimicrobial prophylaxis in clean surgeries for adrenal and renal tumors: Results of the riskâ€based strategy in 1362 consecutive patients. International Journal of Urology, 2021, 28, 1032-1038.	1.0	0
23	Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. Brachytherapy, 2021, 20, 842-848.	0.5	5
24	Infiltrative tumor interface with normal renal parenchyma in locally advanced renal cell carcinoma: Clinical relevance and pathological implications. International Journal of Urology, 2021, 28, 1233-1239.	1.0	7
25	Computer-aided diagnosis with a convolutional neural network algorithm for automated detection of urinary tract stones on plain X-ray. BMC Urology, 2021, 21, 102.	1.4	10
26	Patient-specific virtual and mixed reality forÂimmersive, experiential anatomy education and for surgical planning inÂtemporal bone surgery. Auris Nasus Larynx, 2021, 48, 1081-1091.	1.2	23
27	Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity. World Journal of Urology, 2021, , 1.	2.2	4
28	Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy. International Urology and Nephrology, 2021, 53, 1119-1125.	1.4	5
29	Editorial Comment to Utility of wholeâ€body diffusionâ€weighted magnetic resonance imaging in the management of treatmentâ€related neuroendocrine prostate cancer. IJU Case Reports, 2021, 4, 73-74.	0.3	0
30	Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. Asia-Pacific Journal of Clinical Oncology, 2021, , .	1.1	3
31	Prognostic Accuracy of the qSOFA Score for In-Hospital Mortality in Elderly Patients with Obstructive Acute Pyelonephritis: A Multi-Institutional Study. Diagnostics, 2021, 11, 2277.	2.6	O
32	METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e391-e396.	1.9	12
33	Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy. Clinical Genitourinary Cancer, 2020, 18, 268-273.e2.	1.9	4
34	Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clinical Genitourinary Cancer, 2020, 19, 208-216.e1.	1.9	16
35	Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Medicine, 2020, 9, 8355-8363.	2.8	15
36	Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report. Anti-Cancer Drugs, 2020, 31, 866-871.	1.4	14

#	Article	IF	Citations
37	Patterns of failure after progressive siteâ€directed therapy in oligoâ€progressive castrationâ€resistant prostate cancer. International Journal of Urology, 2020, 27, 634-635.	1.0	5
38	Longitudinal changes in patientâ€reported outcomes after artificial urinary sphincter implantation. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 240-244.	1.3	4
39	Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome. International Journal of Urology, 2020, 27, 395-400.	1.0	6
40	Application of virtual reality in patient explanation of magnetic resonance imaging–ultrasound fusion prostate biopsy. International Journal of Urology, 2020, 27, 471-472.	1.0	8
41	Incidence and Risk Factors of Hypertension Following Partial Nephrectomy in Patients With Renal Tumors: A Cross-sectional Study of Postoperative Home Blood Pressure and Antihypertensive Medications. Clinical Genitourinary Cancer, 2020, 18, e619-e628.	1.9	4
42	Feasibility and outcomes of selective tetramodal bladderâ€preservation therapy in elderly patients with muscleâ€invasive bladder cancer. International Journal of Urology, 2020, 27, 236-243.	1.0	7
43	Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2020, 27, 599-604.	1.0	2
44	Value of extraâ€target prostate biopsy for the detection of magnetic resonance imagingâ€missed adverse pathology according to the Prostate Imaging Reporting and Data System scores: Spatial analysis using magnetic resonance–ultrasound fusion images. International Journal of Urology, 2020, 27, 760-766.	1.0	4
45	Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. International Journal of Radiation Oncology Biology Physics, 2019, 105, 376-381.	0.8	41
46	Editorial Comment to Virtual reality of threeâ€dimensional surgical field for surgical planning and intraoperative management. International Journal of Urology, 2019, 26, 944-944.	1.0	0
47	Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. International Journal of Urology, 2019, 26, 820-826.	1.0	0
48	Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression. European Radiology, 2019, 29, 3881-3888.	4.5	20
49	Selective tetramodal bladderâ€preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscleâ€invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU International, 2019, 124, 242-250.	2.5	35
50	Application of eye tracking as a user interface for urological surgery. International Journal of Urology, 2019, 26, 680-681.	1.0	2
51	Mixed reality computed tomographyâ€based surgical planning for partial nephrectomy using a headâ€mounted holographic computer. International Journal of Urology, 2019, 26, 681-682.	1.0	28
52	Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging. Investigative Radiology, 2019, 54, 638-644.	6.2	25
53	Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. International Journal of Urology, 2019, 26, 273-277.	1.0	11
54	Acute kidney injury and intermediateâ€ŧerm renal function after clampless partial nephrectomy. International Journal of Urology, 2019, 26, 113-118.	1.0	10

#	Article	IF	CITATIONS
55	Clinical outcomes of muscle-invasive bladder cancer patients with hydronephrosis treated with tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy Journal of Clinical Oncology, 2019, 37, 430-430.	1.6	O
56	Intensity ratio curve analysis of small renal masses on T2â€weighted magnetic resonance imaging: Differentiation of fatâ€poor angiomyolipoma from renal cell carcinoma. International Journal of Urology, 2018, 25, 554-560.	1.0	5
57	Prediction of Intraoperative Urinary Collecting System Entry in Patients with Peripheral Renal Tumors Undergoing Partial Nephrectomy: Usefulness of Tumor-Centered Multiplanar Reconstruction. Urologia Internationalis, 2018, 100, 85-91.	1.3	2
58	Adherent Perinephric Fat in Asian Patients: Predictors and Impact on Perioperative Outcomes of Partial Nephrectomy. Urologia Internationalis, 2018, 101, 437-442.	1.3	25
59	Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1408-1416.	0.8	17
60	Computerâ€aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm. BJU International, 2018, 122, 411-417.	2.5	84
61	Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1151-e1158.	1.9	41
62	Multitask Imaging Monitor for Surgical Navigation: Combination of Touchless Interface and Head-Mounted Display. Urologia Internationalis, 2017, 98, 486-488.	1.3	6
63	Utility of computed diffusionâ€weighted MRI for predicting aggressiveness of prostate cancer. Journal of Magnetic Resonance Imaging, 2017, 46, 490-496.	3.4	20
64	DWI as an Imaging Biomarker for Bladder Cancer. American Journal of Roentgenology, 2017, 208, 1218-1228.	2.2	48
65	Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection. Urologia Internationalis, 2017, 98, 298-303.	1.3	6
66	Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes. Clinical Imaging, 2017, 44, 121-126.	1.5	4
67	Realâ€time threeâ€dimensional image angle rectification to improve hand–eye coordination in singleâ€port laparoendoscopic surgery. International Journal of Urology, 2017, 24, 639-640.	1.0	2
68	Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer. American Journal of Roentgenology, 2017, 209, W76-W84.	2.2	42
69	Candidate selection for quadrantâ€based focal ablation through a combination of diffusionâ€weighted magnetic resonance imaging and prostate biopsy. BJU International, 2016, 117, 94-101.	2.5	10
70	A novel interactive educational system in the operating room–the IE system. BMC Medical Education, 2016, 16, 44.	2.4	9
71	Clinical Value of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management. Urologia Internationalis, 2016, 96, 65-72.	1.3	28
72	Novel threeâ€dimensional image system for transurethral surgery. International Journal of Urology, 2015, 22, 714-715.	1.0	5

#	Article	IF	CITATIONS
73	Patient's Self-monitoring of Transurethral Surgical Images Using a Head-mounted Display. Urology Case Reports, 2015, 3, 27-29.	0.3	4
74	A Novel Approach to Surgical Instructions for Scrub Nurses by Using See-Through–Type Head-Mounted Display. CIN - Computers Informatics Nursing, 2015, 33, 335-338.	0.5	7
75	High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. Clinical Genitourinary Cancer, 2015, 13, e243-e251.	1.9	22
76	A Novel Approach to Patient Selfâ€Monitoring of Sonographic Examinations Using a Headâ€Mounted Display. Journal of Ultrasound in Medicine, 2015, 34, 29-35.	1.7	7
77	Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU International, 2015, 115, 705-712.	2.5	43
78	Head-Mounted Display for a Personal Integrated Image Monitoring System: Ureteral Stent Placement. Urologia Internationalis, 2015, 94, 117-120.	1.3	19
79	Novel image monitoring system using a headâ€mounted display for assistants in da Vinci surgery. International Journal of Urology, 2015, 22, 520-521.	1.0	6
80	Application of the RoboSurgeon System in Medical Care. , 2015, , 175-184.		0
81	Gasless Two-Port Access RoboSurgeon Retroperitoneoscopic Radical Nephroureterectomy. , 2015, , 65-84.		1
82	Gasless Single-Port RoboSurgeon Total Cystectomy with Urinary Diversion. , 2015, , 127-141.		1
83	AÂhead-mounted display-based personal integrated-image monitoring system for transurethral resection of the prostate. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 4, 644-649.	0.7	12
84	AÂthree-dimensional head-mounted display system (RoboSurgeon system) for gasless laparoendoscopic single-port partial cystectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 4, 638-643.	0.7	9
85	Technical notes Instructive head-mounted display system: pointing device using aÂvision-based finger tracking technique applied to surgical education. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 3, 449-452.	0.7	15
86	New head-mounted display system applied to endoscopic management of upper urinary tract carcinomas. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 842-845.	1.5	13
87	Pre-operative Risk Stratification for Cancer-specific Survival in Patients with Renal Cell Carcinoma with Venous Involvement Who Underwent Nephrectomy. Japanese Journal of Clinical Oncology, 2014, 44, 756-761.	1.3	10
88	Clinical Application of a Modern Highâ€Definition Headâ€Mounted Display in Sonography. Journal of Ultrasound in Medicine, 2014, 33, 1499-1504.	1.7	18
89	Bone Abnormal Signal Incidentally Found in Pre-Biopsy Diffusion-Weighted MRI for Suspected Prostate Cancer: What Does It Reflect?. Urologia Internationalis, 2014, 93, 170-175.	1.3	4
90	Combination of Diffusion-weighted Magnetic Resonance Imaging and Extended Prostate Biopsy Predicts Lobes Without Significant Cancer: Application in Patient Selection for Hemiablative Focal Therapy. European Urology, 2014, 65, 186-192.	1.9	28

#	Article	IF	CITATIONS
91	Asymmetric Hsp90ÂN Domain SUMOylation Recruits Aha1 and ATP-Competitive Inhibitors. Molecular Cell, 2014, 53, 317-329.	9.7	101
92	Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. International Urology and Nephrology, 2014, 46, 555-561.	1.4	39
93	Role of diffusionâ€weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma. International Journal of Urology, 2014, 21, 1190-1200.	1.0	23
94	Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Selective Bladder-Sparing Approach. International Journal of Radiation Oncology Biology Physics, 2014, 90, 303-311.	0.8	34
95	Functional CT and MRI of the Urinary System and Adrenal Glands. , 2014, , 1173-1182.		1
96	Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report. European Radiology, 2013, 23, 2206-2214.	4.5	33
97	Usefulness of Pre-biopsy Multiparametric Magnetic Resonance Imaging and Clinical Variables to Reduce Initial Prostate Biopsy in Men with Suspected Clinically Localized Prostate Cancer. Journal of Urology, 2013, 190, 502-508.	0.4	65
98	High Diagnostic Ability of Multiparametric Magnetic Resonance Imaging to Detect Anterior Prostate Cancer Missed by Transrectal 12-Core Biopsy. Journal of Urology, 2013, 190, 867-873.	0.4	69
99	Successful reduction of hospital-acquired methicillin-resistant Staphylococcus aureus in a urology ward: a 10-year study. BMC Urology, 2013, 13, 35.	1.4	12
100	Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1604-12.	7.1	217
101	Diabetes Mellitus with Obesity is a Predictor of Recurrence in Patients with Non-metastatic Renal Cell Carcinoma. Japanese Journal of Clinical Oncology, 2013, 43, 740-746.	1.3	17
102	The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models. Cancer Research, 2013, 73, 7022-7033.	0.9	49
103	Zoledronic Acid Sensitizes Renal Cell Carcinoma Cells to Radiation by Downregulating STAT1. PLoS ONE, 2013, 8, e64615.	2.5	19
104	Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle, 2012, 11, 3649-3655.	2.6	23
105	Charged linker sequence modulates eukaryotic heat shock protein 90 (Hsp90) chaperone activity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2937-2942.	7.1	107
106	Role of Diffusion-Weighted Magnetic Resonance Imaging in Predicting Sensitivity to Chemoradiotherapy in Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, e21-e27.	0.8	112
107	Antimicrobial Prophylaxis is Not Necessary in Clean Category Minimally Invasive Surgery for Renal and Adrenal Tumors: A Prospective Study of 373 Consecutive Patients. Urology, 2012, 80, 570-575.	1.0	25
108	Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancerâ€initiating cells. International Journal of Cancer, 2012, 131, 987-996.	5.1	63

#	Article	IF	Citations
109	Selective bladderâ€sparing protocol consisting of induction lowâ€dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscleâ€invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU International, 2012, 109, 860-866.	2.5	55
110	Characteristics and clinical significance of prostate cancers missed by initial transrectal $12\hat{a} \in \mathbb{C}$ ore biopsy. BJU International, 2012, 109, 665-671.	2.5	36
111	ErbB2 and NFκB Overexpression as Predictors of Chemoradiation Resistance and Putative Targets to Overcome Resistance in Muscle-Invasive Bladder Cancer. PLoS ONE, 2011, 6, e27616.	2.5	37
112	Diffusionâ€weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. International Journal of Urology, 2011, 18, 727-730.	1.0	58
113	Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. European Radiology, 2011, 21, 2178-2186.	4.5	157
114	Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle, 2011, 10, 4291-4299.	2.6	30
115	Usefulness of Diffusion-Weighted MRI in Diagnosis of Upper Urinary Tract Cancer. American Journal of Roentgenology, 2011, 196, 110-116.	2.2	43
116	Initial Experience of Diffusion-weighted Magnetic Resonance Imaging to Assess Therapeutic Response to Induction Chemoradiotherapy Against Muscle-invasive Bladder Cancer. Urology, 2010, 75, 387-391.	1.0	97
117	Loss of ΔNp63α Promotes Invasion of Urothelial Carcinomas via N-Cadherin/Src Homology and Collagen/Extracellular Signal-Regulated Kinase Pathway. Cancer Research, 2009, 69, 9263-9270.	0.9	47
118	Discarding antimicrobial prophylaxis for transurethral resection of bladder tumor: A feasibility study. International Journal of Urology, 2009, 16, 61-63.	1.0	18
119	Favourable outcomes of patients with clinical stage T3NOMO bladder cancer treated with induction lowâ€dose chemoâ€radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a singleâ€institutional retrospective comparative study. BJU International, 2009, 104, 189-194.	2.5	40
120	Initial experience of functional imaging of upper urinary tract neoplasm by diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2008, 15, 140-143.	1.0	39
121	Female urethral diverticular abscess clearly depicted by diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2008, 15, 460-461.	1.0	7
122	Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU International, 2008, 101, 775-780.	2.5	87
123	Câ€reactive protein level predicts prognosis in patients with muscleâ€nvasive bladder cancer treated with chemoradiotherapy. BJU International, 2008, 101, 978-981.	2.5	63
124	Low-Dose Chemoradiotherapy Followed by Partial or Radical Cystectomy Against Muscle-Invasive Bladder Cancer: An Intent-to-Treat Survival Analysis. Urology, 2008, 72, 384-388.	1.0	40
125	Absence of prophylactic antibiotics in minimum incision endoscopic urological surgery (MEUS) of adrenal and renal tumors. International Journal of Urology, 2007, 14, 384-387.	1.0	29
126	Discrimination between ureteral stent and stone by non-contrast helical computed tomography in the clinical setting. International Journal of Urology, 2007, 14, 171-173.	1.0	3

#	Article	IF	CITATIONS
127	Threeâ€dimensional assessment of urinary stone on nonâ€contrast helical computed tomography as the predictor of stonestreet formation after extracorporeal shock wave lithotripsy for stones smaller than 20 mm. International Journal of Urology, 2007, 14, 665-667.	1.0	22
128	Bilateral renal angiomyolipoma coexistent with pulmonary lymphangioleiomyomatosis and tuberous sclerosis. International Urology and Nephrology, 2007, 38, 413-415.	1.4	7
129	Role of volume and attenuation value histogram of urinary stone on noncontrast helical computed tomography as predictor of fragility by extracorporeal shock wave lithotripsy. Urology, 2006, 68, 33-37.	1.0	47
130	HtrA2 is up-regulated in the rat testis after experimental cryptorchidism. International Journal of Urology, 2006, 13, 157-164.	1.0	6
131	11C-choline positron emission tomography in bladder cancer: Report of four cases. International Journal of Urology, 2006, 13, 829-831.	1.0	7
132	Asthenospermia in hay fever patients improved by stopping treatment with histamine H1 receptor antagonists. International Journal of Urology, 2006, 13, 1028-1030.	1.0	5
133	Improvement of oligoasthenozoospermia in epileptic patients on switching anti-epilepsy medication from sodium valproate to phenytoin. Scandinavian Journal of Urology and Nephrology, 2005, 39, 431-432.	1.4	12
134	¹¹ C-Choline Positron Emission Tomography in Prostate Cancer: Primary Staging and Recurrent Site Staging. Urologia Internationalis, 2005, 74, 214-220.	1.3	81
135	Malignant pheochromocytoma of the urinary bladder: Effectiveness of radiotherapy in conjunction with chemotherapy. International Journal of Urology, 2004, 11, 175-177.	1.0	13
136	Cystic hamartoma of the renal pelvis. International Journal of Urology, 2004, 11, 653-655.	1.0	13
137	Abscess formation in the prevesical space and bilateral thigh muscles secondary to osteomyelitis of the pubis. Scandinavian Journal of Urology and Nephrology, 2004, 38, 440-441.	1.4	6